CClinicalTrials.gg
CompletedNCT03629535Updated Feb 2, 2021Results posted

Accuracy of Non-invasive Non-oscillometric Blood Pressure Wristband

An interventional study of Non-invasive non-oscillometric blood pressure wristband device and Invasive intra-arterial blood pressure monitors. in Hypotension and Hypertension, sponsored by NYU Langone Health. Completed at 1 site in United States. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2021-02-02.

Sponsored by NYU Langone Health · Not applicable, Interventional, and Diagnostic

Phase
Not applicable
Study type
Interventional
Enrollment
8
Allocation
Not applicable
Ages
18 Years to 100 Years
Sex
All
01

Study summary

The primary objective of the present investigation is to determine the accuracy of a non-invasive non-oscillometric blood pressure wristband device when compared to invasive intra-arterial blood pressure monitors. In an intensive care unit patients who already have an intra-arterial blood pressure monitor in place, this wristband device will be applied and blood pressure readings compared for approximately 15 minutes. Blood pressure readings will be gathered and compared.

02

Conditions studied

  • Hypotension
  • Hypertension

Browse trials for

03

In context

Hypotension

1,003 studies on the registry are indexed under Hypotension; 173 are open to participants now.

This study's enrollment of 8 is below the median of 80 across 675 interventional studies indexed under Hypotension.

Browse Hypotension studies →

Lead sponsor

NYU Langone Health is the lead sponsor of 1,391 studies on the registry; 254 are open to participants now.

Of its 227 completed or terminated interventional studies of FDA-regulated products, 191 (84%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Patients admitted to the Surgical Intensive Care Unit who are already fitted with an invasive Arterial Line (A- Line) are eligible for the trial, and no volunteers candidates for an A Line are requested.

Exclusion criteria

Exclusion Criteria:

  • Within the candidate group of individuals whose procedure in the hospital requires an A-Line, the wristband may not, for various reasons, produce a clean signal. This is immediately determined after wearing the band (and may be related to the size of the wrist of the subject, among other things). Such candidates will be excluded from admission to the study.
  • All data from a subject shall be excluded if the invasive reference systolic blood range is greater than 20 mmHg (2, 67 kPa) or if the invasive reference diastolic range is more than 12 mmHg (1, 6 kPa) in any single determination.
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    Patients in SICU

    Patients in the SICU with an intra-arterial blood pressure monitor already in place will be considered as subjects.

    Device: Non-invasive non-oscillometric blood pressure wristband device · Device: Invasive intra-arterial blood pressure monitors.

Interventions

  • DeviceNon-invasive non-oscillometric blood pressure wristband device

    The device is a band intended to be worn on the wrist for intermittent blood pressure measurements. The device applies no inflatable mechanics or moving parts. The wristband is watertight and can be worn as any type of bracelet.

  • DeviceInvasive intra-arterial blood pressure monitors.

    Because the subjects also have an intra-arterial blood pressure monitor in place, the subjects will serve as their own control

06

What researchers measure

Primary outcomes

  1. Average Error in Blood Pressure Readings

    If the value obtained from the LiveMetric determination lied within the range of the reference BP, an error of 0 mm Hg (0kPa) was assigned to this determination. If the value obtained from the LiveMetric determination lies outside the range of the reference BP, the value of the determination from the adjacent limit of the range of the variation of BP was subtracted. That difference represents the error for this determination. The arithmetic mean of the error is calculated and its experimental standard deviation from the errors of each recording for each BP value (Systolic \& Diastolic) and determination for each patient.

    Time frame: during intervention for 30 minutes

07

Results

Posted Feb 2, 2021

Participant flow

Participant flow — Overall Study
MilestonePatients in SICU
Started8
Completed8
Not completed0

Outcome measures

PrimaryAverage Error in Blood Pressure Readings

If the value obtained from the LiveMetric determination lied within the range of the reference BP, an error of 0 mm Hg (0kPa) was assigned to this determination. If the value obtained from the LiveMetric determination lies outside the range of the reference BP, the value of the determination from the adjacent limit of the range of the variation of BP was subtracted. That difference represents the error for this determination. The arithmetic mean of the error is calculated and its experimental standard deviation from the errors of each recording for each BP value (Systolic \& Diastolic) and determination for each patient.

Time frame:
during intervention for 30 minutes
Reported as:
Mean · mmHg
Average Error in Blood Pressure Readings
mmHgPatients in SICU
Systolic-1.5 ± 6.3
Diastolic3.2 ± 6.0

Adverse events

Collected over during intervention for 30 minutes. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Patients in SICU0/8 (0%)0/8 (0%)0/8 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(years)Patients in SICU
Mean61.6 ± 16.4
Sex: Female, Male
Sex: Female, Male(Participants)Patients in SICU
Female5
Male3
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Patients in SICU
American Indian or Alaska Native0
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American3
White0
More than one race0
Unknown or Not Reported4
Region of Enrollment
Region of Enrollment(participants)Patients in SICU
United States8
08

Study locations

1 site
  • New York University School of Medicine
    New York, New York 10016, United States
09

References and documents

Study documents

  • Protocol and statistical analysis plan · Jul 18, 2019

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: Yes — Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices).

Supporting information: Study protocol, Sap

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 2, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03629535
Lead sponsor
NYU Langone Health
Responsible party
Sponsor
First posted
Aug 14, 2018
Start date
Apr 1, 2019
Primary completion
Sep 10, 2019
Completion
Sep 10, 2019
Results posted
Feb 2, 2021
Last update
Feb 2, 2021

Study contacts

Greta Piper
principal investigator · NYU Langone Health

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion